Isoxazole 9 (ISX-9)

Catalog No.S7914

For research use only.

Isoxazole 9 (Isx-9) is a synthetic promotor of adult neurogenesis by triggering neuronal differentiation of adult neural stem/precursor cells (NSPCs). Isoxazole 9 (Isx-9) activates multiple pathways including TGF-β induced epithelial–mesenchymal transition (EMT) signaling, canonical and non-canonical Wnt signaling at different stages of cardiac differentiation.

Isoxazole 9 (ISX-9) Chemical Structure

CAS No. 832115-62-5

Selleck's Isoxazole 9 (ISX-9) has been cited by 2 Publications

Purity & Quality Control

Choose Selective Wnt/beta-catenin Inhibitors

Other Wnt/beta-catenin Products

Biological Activity

Description Isoxazole 9 (Isx-9) is a synthetic promotor of adult neurogenesis by triggering neuronal differentiation of adult neural stem/precursor cells (NSPCs). Isoxazole 9 (Isx-9) activates multiple pathways including TGF-β induced epithelial–mesenchymal transition (EMT) signaling, canonical and non-canonical Wnt signaling at different stages of cardiac differentiation.
In vitro

In NSPCs, isoxazole 9 increases cell number, and promotes cell differentiation. In OPCs, isoxazole 9 induces cell damage. In outgrowth EPCs, isoxazole 9 decreases tube formation without effect on early EPCs. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HCN MUfGeY5kfGmxbjDhd5NigQ>? NF\ESI9KdmS3Y4Tpc44hd2ZiTl3ERUBz\WOncITvdk1u\WSrYYTl[EBE[TJtIHnu[ox2gCCrbjDyZZQhUEOQIHPlcIx{KGmwIIDy[ZNmdmOnIH;mJG5OTEFicnXj[ZB1d3JiYX70ZYdwdmm|dDDNT|gxOQ>? MnGyQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN MY\GeY5kfGmxbjDhd5NigQ>? NXe1c4FMPSC3TR?= MkDZTY5lfWO2aX;uJI9nKExvdInw[UBk[WylaYXtJINp[W6wZXyvUm1FSSC{ZXPldJRwei2vZXTpZZRm\CCFYUKrJIlv\my3eDDpckBz[XRiSFPOJINmdGy|IHH0JFUhfU1iYomgSpVz[S1{IHntZYdqdmdiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhdXWudHnwcIUhd2ZiaX7obYJqfG:{cx?= NYDUfGdVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OVI5OzJpPkG4OVUzQDN{PD;hQi=>
HCN M3rBb2Z2dmO2aX;uJIF{e2G7 NUnRe|l[PTBidV2= MXWzJIhzew>? NY\UNXlrUW6mdXP0bY9vKG:oIF7NSGEhemWlZYD0c5IudWWmaXH0[YQhdmW3cn;EJIdmdmViZYjwdoV{e2mxbjDpckBz[XRiSFPOJINmdGy|IHH0JFUxKHWPIHHmeIVzKDNiaILzJIJ6KFKWLWDDVkBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjDOUWRCKHKnY3XweI9zKGGwdHHnc45qe3RiTVu4NFE> MnLqQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN MVXGeY5kfGmxbjDhd5NigQ>? MXyyOUB2VQ>? M{HQWFQh\GG7cx?= NEezRlVKdmirYnn0bY9vKG:oIHfsbY9o\W6nc3nzJIRq\m[ncnXueIlifGmxbjDpckBz[XRiSFPOJINmdGy|IHH0JFI2KHWPIHHmeIVzKDRiZHH5dy=> MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN M4\OUWZ2dmO2aX;uJIF{e2G7 MoC1OUB2VQ>? NVPYdpc6UW6mdXP0bY9vKG:oIFyteJlx\SClYXzjbZVuKGOqYX7u[YwwVk2GQTDy[YNmeHSxcj3t[YRq[XSnZDDDZVIsKGmwZnz1fEBqdiC{YYSgTGNPKGOnbHzzJIF1KDVidV2gZpkhTnW{YT2yJIlu[WerbnegZY5idHm|aYO= MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN MWHGeY5kfGmxbjDhd5NigQ>? NGCwVWY2KHWP MW\JcoR2[3Srb36gc4YhVk2GQTDy[YNmeHSxcj3t[YRq[XSnZDDDZVIsKGmwZnz1fEBqdiC{YYSgTGNPKGOnbHzzJIF1KDVidV2gZpkhTnW{YT2yJIlu[WerbnegZY5idHm|aYOgbY4heHKnc3XuZ4Uhd2ZiTl3ERUBz\WOncITvdkBidnSjZ3;ubZN1KE2NOECx MXm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN M4nFWGZ2dmO2aX;uJIF{e2G7 MkLSOVAhfU1? MlroN{BpenN? MkLOTY5lfWO2aX;uJI9nKExvdInw[UBk[WylaYXtJINp[W6wZXyvUm1FSSC{ZXPldJRwei2vZXTpZZRm\CCwZYXyc2Qh\2WwZTDlfJBz\XO|aX;uJIlvKHKjdDDIR24h[2WubIOgZZQhPTBidV2gZYZ1\XJiMzDodpMh[nliUmStVGNTKGGwYXz5d4l{KGmwIIDy[ZNmdmOnIH;mJI12dHSrcHzlJIlvcGmkaYTvdpM> M4X4cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUWyPFMzLz5zOEW1Nlg{OjxxYU6=
HCN MoHQSpVv[3Srb36gZZN{[Xl? MYXJcoR2[3Srb36gc4YhVC22eYDlJINidGOrdX2gZ4hidm6nbD;OUWRCKHKnY3XweI9zNW2nZHnheIVlKEOjMjugbY5ndHW6IHnuJJJifCCKQ16gZ4VtdHN? MkfXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN MWDGeY5kfGmxbjDhd5NigQ>? MYjJcoR2[3Srb36gc4YhVC22eYDlJINidGOrdX2gZ4hidm6nbD;OUWRCKHKnY3XweI9zNW2nZHnheIVlKEOjMjugbY5ndHW6IHnuJJJifCCKQ16gZ4VtdHNiaX6gdJJme2WwY3WgcZVtfGmybHWgbY5pcWKrdH;ydy=> Mo\IQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN M{fxWmZ2dmO2aX;uJIF{e2G7 NHniRVA2OCC3TR?= MljNNlQhcHK| M4jKU2lv\HWldHnvckBw\iCQTVTBJJJm[2WydH;yMY1m\GmjdHXkJI5mfXKxRDDn[Y5mKGW6cILld5Nqd25iaX6gdoF1KEiFTjDj[YxteyCjdDC1NEB2VSCjZoTldkAzPCCqcoOgZpkhWlRvUFPSJIFv[Wy7c3nzJIlvKHC{ZYPlcoNmKG:oIF7NSGEhemWlZYD0c5Ih[W62YXfvcol{fCCPS{iwNS=> NGPifJQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1Nlg{Oid-MUi1OVI5OzJ:L3G+
HCN NYDU[oR[TnWwY4Tpc44h[XO|YYm= M3L2dVUxKHWP NUi1[lljOjRiaILz NXHj[|Q{UW6mdXP0bY9vKG:oIF7NSGEhemWlZYD0c5IudWWmaXH0[YQhdmW3cn;EJIdmdmViZYjwdoV{e2mxbjDpckBz[XRiSFPOJINmdGy|IHH0JFUxKHWPIHHmeIVzKDJ2IHjyd{BjgSCUVD3QR3Ih[W6jbInzbZMhcW5icILld4Vv[2Vib3[gUm1FSSC{ZXPldJRweiCjboTh[49vcXO2IH7p[oVlcXCrbnW= MVK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN NWLLTZRKTnWwY4Tpc44h[XO|YYm= MoH0OVAhfU1? MmPwNlQhcHK| M3rQZ2lv\HWldHnvckBw\iCOLYT5dIUh[2GuY3n1cUBkcGGwbnXsM25OTEFicnXj[ZB1d3JvbXXkbYF1\WRibnX1do9FKGenbnWg[ZhxemW|c3nvckBqdiC{YYSgTGNPKGOnbHzzJIF1KDVyIIXNJIFnfGW{IEK0JIhzeyCkeTDSWE1RS1JiYX7hcJl{cXNiaX6gdJJme2WwY3Wgc4YhdXWudHnwcIUhcW6qaXLpeI9zew>? NGO0dHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1Nlg{Oid-MUi1OVI5OzJ:L3G+
HCN Mk\iSpVv[3Srb36gZZN{[Xl? M{PNXFghfG9iNkSgeW0> MlXBPUBpenN? M3O5cmlv\HWldHnvckBw\iCwZYXyc4dmdmW|aYOgbY4hfW6maX\m[ZJmdnSrYYTl[EBz[XRiSFPOJINmdGy|IHHzd4V{e2WmIHHzJG1CWDKDQjDwdo91\WmwIHzleoVtKGG2IEigeI8hPjRidV2gZYZ1\XJiOTDodpMh[nlicILveIVqdiCkbH;0eIlv\yCjbnHsfZNqew>? MmXYQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN MlTWSpVv[3Srb36gZZN{[Xl? M2fLemlv\HWldHnvckBw\iCKRFHDOUB1emGwc3zvZ4F1cW:wIHnuJIN6fG:ybHHzcUBw\iC{YYSgTGNPKGOnbHzzJIF{e2W|c3XkJIF{KHCqb4PwbI9zgWyjdHXkJGhFSUN3IHHjZ5VufWyjdHnvci=> M1G2[FxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUWyPFMzLz5zOEW1Nlg{OjxxYU6=
HCN MUXGeY5kfGmxbjDhd5NigQ>? NHnkUYNKdmS3Y4Tpc44hd2ZiQ1HNT{1u\WSrYYTl[EBOWkW6MzDhZ5Rqfmm2eTDpckBz[XRiSFPOJINmdGy|IHL5JIx2[2moZYLhd4UhemWyb4L0[ZIh\2WwZTDhd5NigSCrbjDwdoV{\W6lZTDv[kAzNjVidV2gdI91[XO|aYXtJINp[W6wZXygbY5pcWKrdH;yJGtPQTJ? NFvQNpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1Nlg{Oid-MUi1OVI5OzJ:L3G+
HCN MVPGeY5kfGmxbjDhd5NigQ>? NUHQ[JBVQCC2bzC2OEB2VQ>? NH7ZeWw6KGi{cx?= MXjJcoR2[3Srb36gc4YhdmW3cn;n[Y5me2m|IHnuJJVv\GmoZnXy[Y51cWG2ZXSgdoF1KEiFTjDj[YxteyCjc4Pld5Nm\CCjczDHcHIzNzNicILveIVqdiCuZY\lcEBifCB6IITvJFY1KHWPIHHmeIVzKDliaILzJIJ6KHC{b4TlbY4h[myxdITpcoch[W6jbInzbZM> MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN NGTPZW9HfW6ldHnvckBie3OjeR?= M3;VSVYhcHK| NWLBd5c1UW6mdXP0bY9vKG:oIFjERWM2KHCqb4PwbI9zgWyjdHnvckBqdiC{YYSgTGNPKGOnbHzzJIFnfGW{IE[gbJJ{ NXe4fZNrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OVI5OzJpPkG4OVUzQDN{PD;hQi=>
HCN NHvOWnVHfW6ldHnvckBie3OjeR?= NIqxcY0zPCCqcoO= M1K5bmlv\HWldHnvckBw\iCKRFHDOUBxcG:|cHjvdplt[XSrb36gbY4hemG2IFjDUkBk\WyuczDh[pRmeiB{NDDodpM> Mnv2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN Mnv5SpVv[3Srb36gZZN{[Xl? MXfJcoR2[3Srb36gc4YhUESDQ{WgeJJidnOub3PheIlwdiCrbjDueYNt\XW|IH;mJJJifCCKQ16gZ4VtdHNiYYPz[ZN{\WRiYYOgdIhwe3Cqb4L5cIF1\WRiSFTBR|Uh[WOldX31cIF1cW:w NGS3cnA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1Nlg{Oid-MUi1OVI5OzJ:L3G+
HCN M37GVWZ2dmO2aX;uJIF{e2G7 NWX0coxJPSC3TR?= M3Ltb2lv\HWldHnvckBw\iCKRFHDOUB1emGwc3zvZ4F1cW:wIHnuJI52[2yndYOgc4YhemG2IFjDUkBk\WyuczDhd5Nme3OnZDDhd{BITlBvSFTBR|UhWzJ3OFGgV|Q6QEFibYX0ZY51KG[3c3nvckBxem:2ZXnuJIFk[3WvdXzheIlwdiCjdDC1JJVOKGK7IH\seY9z\XOlZX7j[UBie3OjeR?= NFHQT5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1Nlg{Oid-MUi1OVI5OzJ:L3G+
HCN NXnQ[5h1TnWwY4Tpc44h[XO|YYm= MmTtOVAhfU1? NHS4O3o{KGi{cx?= NViwN2ZDUW6mdXP0bY9vKG:oIF7NSGEhemWlZYD0c5IudWWmaXH0[YQhdmW3cn;EJIdmdmViZYjwdoV{e2mxbjDpckBz[XRiSFPOJINmdGy|IHH0JFUxKHWPIHHmeIVzKDNiaILzJIJ6KFKWLWDDVkBidmGueYPpd{BqdiCycnXz[Y5k\SCxZjDOUWRCKHKnY3XweI9zKGGwdHHnc45qe3Ribnnm[YRqeGmwZR?= MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN M1m5N2Z2dmO2aX;uJIF{e2G7 M17xNVIxKHWP MYXJcoR2[3Srb36gc4YhUESDQ{WgeJJidnOub3PheIlwdiCrbjDueYNt\XW|IH;mJJJifCCKQ16gZ4VtdHNiYYPz[ZN{\WRiYYOgS2ZRNUiGQVO1JIZ2e2mxbjDwdo91\WmwIHHjZ5VufWyjdHnvckBifCB{MDD1UUBjgSCobIXvdoV{[2WwY3WgZZN{[Xl? NIi1Upg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1Nlg{Oid-MUi1OVI5OzJ:L3G+
HCN NU\udIduTnWwY4Tpc44h[XO|YYm= MmfsTY5lfWO2aX;uJI9nKEODTVutcYVlcWG2ZXSgUXJGgDNiYXP0bZZqfHliaX6gdoF1KEiFTjDj[YxteyCkeTDseYNq\mW{YYPlJJJmeG:{dHXyJIdmdmViYYPzZZkhcW5icILld4Vv[2Vib3[gNlAxKG6PIGDLR{BqdmirYnn0c5IhT294OUe2 MUO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MkizNkc,OTh3NUK4N|I9N2F-
HCN M4\pemZ2dmO2aX;uJIF{e2G7 NFX5fYgzPCCqcoO= M3LhXGlv\HWldHnvckBw\iCOLYT5dIUh[2GuY3n1cUBkcGGwbnXsMY1m\GmjdHXkJI5mfXKxRDDn[Y5mKGW6cILld5Nqd25iaX6gdoF1KEiFTjDj[YxteyCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7IHnuJJBz\XOnbnPlJI9nKG23bITpdIxmKGmwaHnibZRwenN? NWru[YNMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi1OVI5OzJpPkG4OVUzQDN{PD;hQi=>
HCN NITFZnNHfW6ldHnvckBie3OjeR?= NF:5UIozPCCqcoO= NHPYcWRKdmS3Y4Tpc44hd2ZiTD30fZBmKGOjbHPpeY0h[2ijbn7lcE1u\WSrYYTl[EBv\XW{b1Sg[4Vv\SCneIDy[ZN{cW:wIHnuJJJifCCKQ16gZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KGy3Y3nm[ZJie2VicnXwc5J1\XJiZ3Xu[UBie3OjeTDpckBxemW|ZX7j[UBw\iCQTVTBJJJm[2WydH;yJIFvfGGpb37pd5QhVUt6MEG= Mn\iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUK4N|IoRjF6NUWyPFMzRC:jPh?=
HCN MofESpVv[3Srb36gZZN{[Xl? M{eyTFI1KGi{cx?= M4nvcGlv\HWldHnvckBw\iCOLYT5dIUh[2GuY3n1cUBkcGGwbnXsMY1m\GmjdHXkJI5mfXKxRDDn[Y5mKGW6cILld5Nqd25iaX6gdoF1KEiFTjDj[YxteyCjZoTldkAzPCCqcoOgZpkhdHWlaX\ldoF{\SC{ZYDvdpRmeiCpZX7lJIF{e2G7IHnuJJBz\XOnbnPlJI9nKE6PRFGgdoVk\XC2b4KgZY51[WexbnnzeEBvcW[nZHnwbY5m M1jjN|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NUWyPFMzLz5zOEW1Nlg{OjxxYU6=
In vivo In mice, isoxazole 9 (20 mg/kg, i.p.) crosses the BBB and increases proliferation of neuroblasts and neurogenesis via Mef2-specific mechanisms in the hippocampal SGZ. Isoxazole 9 (20 mg/kg, i.p.) also increases differentiation and dendritic complexity of immature neurons and improves memory. In MWM, isoxazole 9 improves spatial memory. [2]

Protocol (from reference)

Cell Research:[1]
  • Cell lines: NSPCs, OPCs, early EPCs, and outgrowth EPCs
  • Concentrations: ~50 μM
  • Incubation Time: 48 h
  • Method: Cells are treated with different concentrations of Isx-9 (0, 6.25, 12.5, 25, or 50 μM), and 2 days later, cell numbers are counted in a blinded manner to evaluate the effects of Isx-9 on the proliferation/survival of four types of progenitor/precursor cells.
Animal Research:[2]
  • Animal Models: Transgenic Nkx2.5-luciferase reporter mice
  • Dosages: 20 mg/kg
  • Administration: i.p.

Solubility (25°C)

In vitro

In vivo

Add solvents to the product individually and in order
(Data is from Selleck tests instead of citations):
5% DMSO+55% PEG 300+ddH2O
For best results, use promptly after mixing.

10mg/mL

Chemical Information

Molecular Weight 234.27
Formula

C11H10N2O2S

CAS No. 832115-62-5
Storage 3 years -20°C powder
2 years -80°C in solvent
Smiles C1CC1NC(=O)C2=NOC(=C2)C3=CC=CS3

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.
Tags: buy Isoxazole 9 (ISX-9) | Isoxazole 9 (ISX-9) supplier | purchase Isoxazole 9 (ISX-9) | Isoxazole 9 (ISX-9) cost | Isoxazole 9 (ISX-9) manufacturer | order Isoxazole 9 (ISX-9) | Isoxazole 9 (ISX-9) distributor